Inhibrx Biosciences (INBX) Long-Term Debt Issuances (2025)
Inhibrx Biosciences' (INBX) quarterly Long-Term Debt Issuances came in at $100.0 million in Q1 2025.
Inhibrx Biosciences (INBX) Long-Term Debt Issuances (2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 1 years of Long-Term Debt Issuances data on file, last reported at $100.0 million in Q1 2025.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $100.0 million in Q1 2025; TTM through Dec 2025 was $100.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $100.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q1 2025 stood at $100.0 million.
- Over the last five years, Long-Term Debt Issuances for INBX reached as high as $100.0 million in Q1 2025 and fell as low as $100.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 99.97 Mn |
| Mar 31, 2025 | 99.97 Mn |